1. Pharmaceutical Salts and Co-crystals, Royal Society of Chemistry (2012). Edited by Johan Wouters and Luc Qu’er’e

2.US patent: Berkenstam et al. US 7,863,325 B2. Jan 4 , 2011

3. Taylor, C. K., Levy, R. M., Elliott, J.C. and Burnett, B. P (2009). The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr. Rev. 67, 398-415.

4. Lethaby, A., Marjoribanks, J., Kronenberg, H., Roberts, H., Eden, J. and Brown, J. (2013). Phytoestrogens for menopausal symptoms. Cochrane Database Syst. Rev. 12, 2013.

5. Bitto, A., Polito, F., Marini, H., D’Anna, R., Irrera, N., Minutoli, L., Granese, R. Altavilla, D. (2010). Genistein agycone: a dual mode of action anti-osteoporotic soy isoflavone rebalancing bone turnover towards bone formation. Curr. Med. Chem., 27, 3007-3018.

6.Malinowska, M., Wilkinson, F. M., Langford-Smith, K. J., Langford-Smith, A., Brown, J. R., Crawford, B. E., Vanier, M. T., Grynkiewicz, G., Wynn, R. F., Wraith, J.E., Wegrzyn, G. and Bigger, B. B. (2010), Genistein improves neuropathology and corrects bahaviour in a mouse model of neurodegenetaive metabolic disease. PLos ONE, 5, 1-9

7. Ullman, U., Metzner, J., Frank, T., Chon, A. and Riegger, C. (2005). Safety, tolerability, and pharmacolinetics of single ascending doses of synthetic genistein (BonisteinTM ) in healthy volunteers. Advances in Natural Therapy, 22, 65-78

8. Burns, K. A. and Korach, K. S. (2012). Estrogen receptors and human disease: an update. Arch. Toxicol. 86, 1491-1504

9. National Cancer Institute.

10. Ghosn, M., Kourie, H. R., El Karak, F., Hanna, C., Antoun, J. and Nasr, D. (2014). Optimum chemotherapy in the management of metastatic pancreatic cancer. Worl J. Gastroenterol. 20, 2352-2357.

11. Buchler, P., Gukovskaya, A. S., Mouria, M., Buchler, M. C., Buchler, M. W., Friess, H., Pandol, S. J., Reber, H. A. and Hines, O.J. (2003). Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas 26, 264-273

12. Pavese, J. M., Farmer, R. L. and Bergan, R. C. (2010). Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 29, 465–482

13. Banerjee, S., Zhang, Y., Ali, S., Chiao, P. J., Philip, P. A., Abbruzzese, J. and Sarkar, F. H. (2005) Cancer Res. 2005 Oct 1;65(19):9064-72. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.Cancer Res. 65, 9064-72.

14. El-Rayes, B. F., Ali, S., Ali, I. F., Philip, P. A., Abbruzzese, J. and Sarkar, F. H. (2006). Potentiation of the effect of erlotinib by genistein in pancreatic cancer: The role of Akt and Nuclear Factor-B. Cancer Res. 66, 10553-10559

15. Banerjee, S., Kong, D., Asfar S. A., Wang, Z., Ahmas, A., Sethi, S. and Sarkar, F. H. (2010) Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. 1240-1250.

16. de Ruijter, J., Valstar, M. J. and Wijburg, F. A. (2011) Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Curr. Pharm. Biotech. 12, 923-930

19. Axcentua granted orphan drug status